Next 10 |
2024-05-08 09:17:03 ET A %Biotech company is turning heads so far during Wednesday’s premarket hours following the company reporting higher than expected revenue and EPS. According to a handful of releases, the company’s EPS of $0.30 beat estimates by a staggering $0.32, a...
2024-05-07 17:49:11 ET More on Repare Therapeutics Repare Therapeutics appoints Steven Stein to its board of directors Repare to regain global rights to camonsertib from Roche Seeking Alpha’s Quant Rating on Repare Therapeutics Historical earnings data...
Phase 1 MYTHIC clinical trial of lunresertib in combination with camonsertib demonstrated a significant reduction in Grade 3 anemia and continued trends of patient response and benefit; FDA agrees with RP2D First patient dosed in Phase 1 MYTHIC clinical trial of lunresertib in combination...
Debiopharm ( www.debiopharm.com ), a privately-owned, Swiss-based biopharmaceutical company aiming to establish tomorrow’s standards of care to cure cancer and infectious diseases , and Repare Therapeutics Inc. (“Repare”) (Nasdaq: RPTX), a leading clinical-stage p...
Repare Therapeutics Inc. (“Repare” or the “Company”) (Nasdaq: RPTX), a leading clinical-stage precision oncology company, and Debiopharm ( www.debiopharm.com ), a privately-owned, Swiss-based biopharmaceutical company aiming to establish tomorrow’s standards...
2024-04-26 16:18:41 ET More on Repare Therapeutics Repare to regain global rights to camonsertib from Roche Seeking Alpha’s Quant Rating on Repare Therapeutics Historical earnings data for Repare Therapeutics Financial information for Repare Therapeuti...
Repare Therapeutics Inc. (“Repare” or the “Company”) (Nasdaq: RPTX), a leading clinical-stage precision oncology company, today announced the appointment of Steven H. Stein, M.D., to its Board of Directors, effective as of the date of the Company’s upcoming annu...
NEW YORK, NY / ACCESSWIRE / March 15, 2024 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Repare Therapeutics Inc. ("Repare" or "the Company") (NASDAQ:RPTX). Investors who purchased Repare securities are encouraged to obtain additional infor...
Repare Therapeutics Inc. (“Repare” or the “Company”) (Nasdaq: RPTX), a leading clinical-stage precision oncology company, today reported financial results for the fourth quarter and full year ended December 31, 2023. “2023 was a year of substantial progress ...
First Solar Inc. (FSLR) is expected to report $3.19 for Q4 2023 VIZIO Holding Corp. Class A (VZIO) is expected to report $0.02 for Q4 2023 Henry Schein Inc. (HSIC) is expected to report $0.71 for Q4 2023 Republic Services Inc. (RSG) is expected to report $1.28 for Q4 2023 Forge Gl...
News, Short Squeeze, Breakout and More Instantly...
Repare Therapeutics Inc. Company Name:
RPTX Stock Symbol:
NASDAQ Market:
Shares of Upstart Holdings, Inc. (NASDAQ:UPST) fell sharply during Wednesday's session after the company reported first-quarter financial resu...
Shares of RingCentral, Inc. (NYSE:RNG) rose sharply in today's pre-market trading after the company reported better-than-expected first-quarte...
2024-05-08 09:17:03 ET A %Biotech company is turning heads so far during Wednesday’s premarket hours following the company reporting higher than expected revenue and EPS. According to a handful of releases, the company’s EPS of $0.30 beat estimates by a staggering $0.32, a...